The BROADWAY trial shows that obicetrapib significantly lowers LDL cholesterol and Lp(a) in high-risk cardiovascular patients, offering a safe and effective option beyond current lipid-lowering therapies.
Most Recent Articles
VISUALIZED: Evolocumab Reduces Coronary Plaque Inflammation and Volume in CAD Patients
Read further: Evolocumab Reduces Coronary Plaque Inflammation and Volume in CAD Patients
Regional Differences in Burnout Among U.S. Internal Medicine Physicians
Burnout affects internal medicine physicians across all practice settings. Still, regional differences—especially higher rates in the Western U.S.—highlight the need for location-specific strategies to support clinician well...
Plant-Based Diet Reduces Body Weight and HbA1c in Type 2 Diabetes Patients
A 12-week online plant-based diet program significantly reduced body weight, HbA1c, and cholesterol in type 2 diabetes patients, highlighting its potential as a cost-effective clinical intervention.
Probiotics as a Potential Intervention for Alzheimer’s Disease: Effects on Cognitive Decline and Inflammation
Probiotic treatment in Alzheimer’s mouse models reduced cognitive decline and inflammation. At the same time, human data linked age-related changes in gut viruses to dementia, highlighting the gut-brain axis as a promising...